Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor

被引：2

作者：

Coskun, Hasan Senol ^{[1
,2
,3
]}

Goeksu, Sema Sezgin ^{[1
,2
,3
]}

Sahin, Mehmet ^{[1
,2
,3
]}

Alanoglu, Guechan ^{[1
,2
,3
]}

机构：

[1] Suleyman Demirel Univ, Dept Med Oncol, Fac Med, TR-32041 Isparta, Turkey

[2] Suleyman Demirel Univ, Dept Hematol, Fac Med, TR-32041 Isparta, Turkey

[3] Suleyman Demirel Univ, Dept Immunol, Fac Med, TR-32041 Isparta, Turkey

来源：

MEDICAL ONCOLOGY | 2008年 / 25卷 / 01期

关键词：

CML; imatinib; combination chemotherapy;

D O I：

10.1007/s12032-007-0053-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Imatinib is now indicated as the first line therapy for chronic myeloid leukemia (CML). Treatment of CML with imatinib is generally well tolerated and the risk of severe adverse affects is low. Many new drugs including targeted therapy are combined with antineoplastic agents safely. We here report a patient with CML who developed concurrent mesenchymal tumor while undergoing therapy with imatinib and treated with combination chemotherapy including bleomycin, etoposide, and cisplatin, as well as imatinib without severe toxicity.

引用

页码：110 / 112

页数：3

共 12 条

[1] Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia:: results of the GRAAPH-2003 study [J].

de Labarthe, Adrienne ;

Rousselot, Philippe ;

Huguet-Rigal, Francoise ;

Delabesse, Eric ;

Witz, Francis ;

Maury, Sebastien ;

Rea, Delphine ;

Cayuela, Jean-Michel ;

Vekemans, Marie-Christine ;

Reman, Oumedaly ;

Buzyn, Agnes ;

Pigneux, Arnaud ;

Escoffre, Martine ;

Chalandon, Yves ;

MacIntyre, Elizabeth ;

Lheritier, Veronique ;

Vernant, Jean-Paul ;

Thomas, Xavier ;

Ifrah, Norbert ;

Dombret, Herve .

BLOOD, 2007, 109 (04) :1408-1413

[2] Acute renal failure secondary to imatinib mesylate treatment in prostate cancer [J].

Foringer, JR ;

Verani, RR ;

Tjia, VM ;

Finkel, KW ;

Samuels, JA ;

Guntupalli, JS .

ANNALS OF PHARMACOTHERAPY, 2005, 39 (12) :2136-2138

[3] Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours [J].

George, Suzanne ;

Desai, Jayesh ;

Eder, J. Paul ;

Manola, Judith ;

Ryan, Dauid P. ;

Appleman, Leonard J. ;

Demetri, George D. .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (07) :864-870

[4] Indications for imatinib mesylate therapy and clinical management [J].

Guilhot, F .

ONCOLOGIST, 2004, 9 (03) :271-281

[5] Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma [J].

Johnson, FM ;

Krug, LM ;

Tran, HT ;

Shoaf, S ;

Prieto, VG ;

Tamboli, P ;

Peeples, B ;

Patel, J ;

Glisson, BS .

CANCER, 2006, 106 (02) :366-374

[6] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. [J].

Kantarjian, H ;

Sawyers, C ;

Hochhaus, A ;

Guilhot, F ;

Schiffer, C ;

Gambacorti-Passerini, C ;

Niederwieser, D ;

Resta, D ;

Capdeville, R ;

Zoellner, U ;

Talpaz, M ;

Druker, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :645-652

[7] Elderly patients with PH+ chronic myelogenous leukemia (CML): Results of imatinib mesylate treatment (vol 29, pg 287, 2005) [J].

Latagliata, R ;

Breccia, M ;

Carmosino, I ;

Sarlo, C ;

Montefusco, E ;

Mancini, M ;

Natalino, F ;

Chistolini, A ;

De Cuia, R ;

Russo, E ;

Morano, GS ;

Biondo, F ;

Spadea, A ;

Mandelli, F ;

Alimena, G .

LEUKEMIA RESEARCH, 2005, 29 (09) :1099-1099

[8] High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia [J].

Rea, D ;

Legros, L ;

Raffoux, E ;

Thomas, X ;

Turlure, P ;

Maury, S ;

Dupriez, B ;

Pigneux, A ;

Choufi, B ;

Reman, O ;

Stéphane, D ;

Royer, B ;

Vigier, M ;

Ojeda-Uribe, M ;

Recher, C ;

Dombret, H ;

Huguet, F ;

Rousselot, P .

LEUKEMIA, 2006, 20 (03) :400-403

[9] Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study [J].

Sawyers, CL ;

Hochhaus, A ;

Feldman, E ;

Goldman, JM ;

Miller, CB ;

Ottmann, OG ;

Schiffer, CA ;

Talpaz, M ;

Guilhot, F ;

Deininger, MWN ;

Fischer, T ;

O'Brien, SG ;

Stone, RM ;

Gambacorti-Passerini, CB ;

Russell, NH ;

Reiffers, JJ ;

Shea, TC ;

Chapuis, B ;

Coutre, S ;

Tura, S ;

Morra, E ;

Larson, RA ;

Saven, A ;

Peschel, C ;

Gratwohl, A ;

Mandelli, F ;

Ben-Am, M ;

Gathmann, I ;

Capdeville, R ;

Paquette, RL ;

Druker, BJ .

BLOOD, 2002, 99 (10) :3530-3539

[10] Hematological side effects of tyrosine kinase inhibition using imatinib [J].

Schmitt-Graeff A. ;

Hochhaus A. .

Der Pathologe, 2006, 27 (1) :40-46

← 1 2 →